Wednesday, December 1, 2021

Which glioblastoma patients will respond to immunotherapy?

Scientists have discovered a new biomarker to identify which patients with brain tumors called glioblastomas -- the most common and malignant of primary brain tumors -- might benefit from immunotherapy. The treatment could extend survival for an estimated 20% to 30% of patients. Currently, patients with glioblastoma do not receive this life-prolonging treatment because it has not been fully understood which of them could benefit.

from Top Health News -- ScienceDaily https://ift.tt/3xHyLjg
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

This “master gene” may be driving pancreatic cancer’s spread

A gene called KLF5 may be a key force behind the spread of pancreatic cancer—but not in the way scientists expected. Rather than mutating DN...